Elutia Inc. (ELUT) - Total Liabilities
Based on the latest financial reports, Elutia Inc. (ELUT) has total liabilities worth $73.33 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ELUT cash flow conversion to assess how effectively this company generates cash.
Elutia Inc. - Total Liabilities Trend (2018–2024)
This chart illustrates how Elutia Inc.'s total liabilities have evolved over time, based on quarterly financial data. See shareholders equity of Elutia Inc. for net asset value and shareholders' equity analysis.
Elutia Inc. Competitors by Total Liabilities
The table below lists competitors of Elutia Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
M K Land Holdings Bhd
KLSE:8893
|
Malaysia | RM537.75 Million |
|
Quality & Reliability A.B.E.E
AT:QUAL
|
Greece | €15.77 Million |
|
Rank Progress S.A.
WAR:RNK
|
Poland | zł332.60 Million |
|
Arlitech Electronic
TWO:6432
|
Taiwan | NT$457.37 Million |
|
Snow Lake Resources Ltd
NASDAQ:LITM
|
USA | $11.14 Million |
|
Pan Global Resources Inc
V:PGZ
|
Canada | CA$871.00K |
|
Demisas Dokum Emaye Mamulleri Sanayi AS
IS:DMSAS
|
Turkey | TL1.51 Billion |
|
Woosung Feed
KO:006980
|
Korea | ₩228.06 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Elutia Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Elutia Inc. worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Elutia Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Elutia Inc. (2018–2024)
The table below shows the annual total liabilities of Elutia Inc. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $82.39 Million | +0.44% |
| 2023-12-31 | $82.03 Million | +11.04% |
| 2022-12-31 | $73.87 Million | +37.70% |
| 2021-12-31 | $53.65 Million | -13.44% |
| 2020-12-31 | $61.98 Million | -37.95% |
| 2019-12-31 | $99.88 Million | +9.58% |
| 2018-12-31 | $91.15 Million | -- |
About Elutia Inc.
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators;… Read more